GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Results of Operations and Financial ConditionItem 2.02
The Company hereby incorporates by reference herein the information set forth in its press release dated August18, 2017 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
| Item 2.02 | Financial Statements and Exhibits. |
|
Exhibit Number |
Description |
| 99.1 | Press Release dated August 18, 2017 |
GALECTIN THERAPEUTICS INC ExhibitEX-99.1 2 d445123dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update NORCROSS,…To view the full exhibit click here
About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.